Supreme Court Rejects Juno, Welcomes Amgen Back to Patent Discussions
In an eventful week for pharma, the U.S. Supreme Court denied Juno Therapeutics’ request to reinstate a $1.2 billion award from Kite in a patent dispute. The Supreme Court also announced it would listen to Amgen’s bid to revive the patents for a cholesterol drug, Repatha, after a lawsuit with Sanofi and Regeneron.
It's free! Log in now to read
LATEST
Neurosurgery Now: NVIDIA’s Holoscan AI Brings Real-Time 3D Vision to Enhance Surgical Precision at 2025 GTC
2025-03-18
NVIDIA GTC 2025: BioMap’s xTrimo — The AI Model That’s Changing Biotech and Drug Discovery
2025-03-18